SCHEMBL3606619

SCHEMBL3606619

CC(C)(C)OC(=O)N1CCc2cc(NC(=O)c3cnn(Cc4ccc(Cl)c(Cl)c4)c3)ccc2C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMPRSS2 O15393 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 2/20 0.49
MEN1 O00255 1/20 0.49
TP53 P04637 1/20 0.49
HPGD P15428 1/20 0.49
KMT2A Q03164 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
MAPT P10636 2/20 0.48
PLA2G1B P04054 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
ATG4B Q9Y4P1 1/20 0.48
ESR2 Q92731 1/20 0.47
NOD1 Q9Y239 1/20 0.45
SCD O00767 1/20 0.45
SCD5 Q86SK9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3596504 0.91 SMN1; SMN2 (0.57) TMPRSS2SMN1; SMN2LMNAMEN1TP53
SCHEMBL3603275 0.91 NAMPT (0.49) TMPRSS2SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL3608816 0.90 SCD (0.55) TMPRSS2LMNAESR2SCDSCD5
SCHEMBL13945301 0.87 KDM1A (0.52) TMPRSS2MAPTESR2NOD1SCD
SCHEMBL13845013 0.86 MAPT (0.43) SMN1; SMN2LMNAMEN1TP53HPGD
SCHEMBL3602454 0.85 RAF1 (0.47) MAPTESR2SCDSCD5NAMPT
SCHEMBL3602270 0.85 ESR2 (0.46) TMPRSS2MEN1KMT2AESR2NOD1
SCHEMBL3599020 0.84 SMN1; SMN2 (0.57) TMPRSS2SMN1; SMN2LMNAMEN1TP53
SCHEMBL3600668 0.84 ESR2 (0.46) TMPRSS2SMN1; SMN2TP53MAPTESR2
SCHEMBL3603596 0.82 SCD (0.53) TMPRSS2SMN1; SMN2LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487108-B2 Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-07-16 US disclosed
EP-1966139-B1 ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS INC (US) 2011-12-21 EP disclosed
US-20100048636-A1 Aspartic Protease Inhibitors VITAE PHARMACEUTICALS, INC. 2010-02-25 US disclosed
US-20100041696-A1 Compounds SMITHKLINE BEECHAM CORPORATION 2010-02-18 US disclosed
US-20100041696-A1 Compounds SMITHKLINE BEECHAM CORPORATION 2010-02-18 US disclosed
US-20100041696-A1 Compounds SMITHKLINE BEECHAM CORPORATION 2010-02-18 US disclosed
EP-1966139-A1 ASPARTIC PROTEASE INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2008-09-10 EP disclosed
WO-2008074824-A2 ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) SMITHKLINE BEECHAM CORPORATION (US) 2008-06-26 WO disclosed
WO-2007070201-A1 ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048636-A1 Aspartic Protease Inhibitors DNPEP, PEPD, SERPINB1 TMPRSS2 53/4885SMN1; SMN2 1372/4885LMNA 4613/4885
US-20100041696-A1 Compounds CYP11B2, SCD, CYP3A5 TMPRSS2 2074/4885SMN1; SMN2 618/4885LMNA 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.